When peripheral neuropathy occurs due to chemotherapy treatment, it is referred to as
chemotherapy-induced peripheral neuropathy (CIPN). Typically, symptoms are sensory …

Opinion statement Chemotherapy-induced peripheral neuropathy (CIPN) is a common
toxicity associated with treatment with platinum-based agents, taxanes, vinca alkaloids, and …

Importance Chemotherapy-induced peripheral neuropathy (CIPN), one of the most common
and severe adverse effects of chemotherapy, is associated with worse quality of life among …

Chemotherapy-induced neuropathic pain (CINP) is one of the most severe side effects of
anticancer agents, such as platinum-and taxanes-derived drugs (oxaliplatin, cisplatin …

Oxidative stress, resulting from an imbalance between the formation of damaging free
radicals and availability of protective antioxidants, can contribute to peripheral neuropathic …

Chemotherapy-induced peripheral neuropathy (CIPN) is a common and dose-limiting
toxicity, negatively affecting both quality of life and disease outcomes. To date, there is no …

Purpose To conduct a systematic review and meta-analysis of current studies to determine
whether exercise affects chemotherapy-induced peripheral neuropathy (CIPN) symptoms in …

Chemotherapy-induced peripheral neuropathy (CIPN) is a disabling side effect caused by
neurotoxic chemotherapy. This randomized controlled trial aimed to evaluate the effect of …

Opioids are employed in the management of chemotherapy-induced neuropathic pain
(CINP) when other pain management approaches have failed and proven ineffective …

Although the immunotherapy advent has revolutionized cancer treatment, it, unfortunately,
does not spare cancer patients from possible immune-related adverse events (irAEs), which …